Symbols

BDSX

Biodesix·NASDAQ

--(--)

BDSX fundamentals

BDSX Q4 2025 Earnings

Biodesix (BDSX) released its earnings on Feb 26, 2026: revenue was 28.75M (YoY +40.76%), beat estimates; EPS was -0.49 (YoY +59.17%), beat estimates.

Revenue / YoY

28.75M

+40.76%

EPS / YoY

-0.49

+59.17%

Report date

Feb 26, 2026

BDSX Earnings Call Summary for Q4,2025

Revenue Growth: 41% YoY in Q4, driven by 46% lung diagnostics and 41% development services expansion.
Profitability Milestone: First positive adjusted EBITDA ($530K) and 83% gross margin, supported by 97-rep sales force.
Strategic Expansion: Primary care penetration (12% of tests) and partnerships with Thermo Fisher/Bio-Rad fuel pipeline growth.
2026 Outlook: $106-112M revenue target (+23% YoY), with focus on sales productivity and reimbursement optimization.

Earnings

EPS

Revenue

Revenue & Expenses

BDSX has released its 2025 Q4 earnings report, with revenue of 28.75M, reflecting a YoY change of 40.76%, and net profit of -3.98M, showing a YoY change of 51.76%. The Sankey diagram below clearly presents BDSX's revenue sources and cost distribution.

Key Indicators

Biodesix (BDSX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Biodesix (BDSX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Biodesix (BDSX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Biodesix (BDSX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown